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Abstract
Background: Subcutaneous peginterferon beta-1a has previously been shown to reduce the number of T2-hyperintense
and gadolinium-enhancing (Gd+) lesions over 2 years in patients with relapsing-remitting multiple sclerosis (RRMS),
and to reduce T1-hypointense lesion formation and the proportion of patients showing evidence of disease activity,
based on both clinical and radiological measures, compared with placebo over 1 year of treatment. The objectives of
the current analyses were to evaluate T1 lesions and other magnetic resonance imaging (MRI) measures, including
whole brain volume and magnetization transfer ratio (MTR) of normal appearing brain tissue (NABT), and the
proportions of patients with no evidence of disease activity (NEDA), over 2 years.
Methods: Patients enrolled in the ADVANCE study received continuous peginterferon beta-1a every 2 or 4 weeks
for 2 years, or delayed treatment (placebo in Year 1; peginterferon beta-1a every 2 or 4 weeks in Year 2). MRI scans
were performed at baseline and Weeks 24, 48, and 96. Proportions of patients with NEDA were calculated based
on radiological criteria (absence of Gd + and new/newly-enlarging T2 lesions) and clinical criteria (no relapse or
confirmed disability progression) separately and overall.
Results: Peginterferon beta-1a every 2 weeks significantly reduced the number and volume of T1-hypointense
lesions compared with delayed treatment over 2 years. Changes in whole brain volume and MTR of NABT were
suggestive of pseudoatrophy during the first 6 months of peginterferon beta-1a treatment, which subsequently
began to resolve. Significantly more patients in the peginterferon beta-1a every 2 weeks group compared with
the delayed treatment group met MRI-NEDA criteria (41% vs 21%; odds ratio [OR] 2.56; p < 0.0001), clinical-NEDA
criteria (71% vs 57%; OR 1.90; p < 0.0001) and achieved overall-NEDA (37% vs 16%; OR 3.09; p < 0.0001).
Conclusion: Peginterferon beta-1a provides significant improvements in MRI measures and offers patients a good
chance of remaining free from evidence of MRI, clinical and overall disease activity over a sustained 2-year period.
Trial registration: ClinicalTrials.gov: NCT00906399; Registered on: May 20, 2009.
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Background
Interferon beta-1a is a therapeutic protein that has been
used for many years as an effective treatment for mul-
tiple sclerosis (MS). A limitation is the need for frequent
administration and associated injection-site adverse
events [1]. Attachment of polyethylene glycol (PEG)
molecules (pegylation) has been shown to improve the
pharmacokinetic and pharmacodynamic properties of
protein therapeutics, including interferon beta-1a [2, 3].
The approved dosing schedule of pegylated interferon
beta-1a (peginterferon beta-1a) for relapsing-remitting
multiple sclerosis (RRMS) of one subcutaneous (SC)
injection every 2 weeks is less frequent than other cur-
rently available injectable therapies [2–4].
The efficacy and safety of peginterferon beta-1a in pa-
tients with RRMS were demonstrated in the ADVANCE
study, a 2-year, Phase 3, multicenter study with a 1-year
placebo-controlled period. In Year 1, peginterferon
beta-1a (125 mcg SC) administered every 2 or 4 weeks
resulted in a significantly lower annualized relapse rate
(ARR), risk of relapse, and 12-week confirmed disability
progression than placebo, with a safety profile similar
to established interferon beta-1a therapies [5]. After
96 weeks of treatment, ARR was further reduced in
patients who continued on peginterferon beta-1a every
2 weeks, and was maintained in the every 4 weeks
treatment group [6]. Magnetic resonance imaging
(MRI) results reflected the clinical findings, showing
that peginterferon beta-1a every 2 weeks significantly
reduced the mean number of new or newly enlarging
T2 hyperintense lesions, new T1 hypointense lesions,
and gadolinium-enhancing (Gd+) lesions, and the mean
volume of T2 hyperintense and T1 hypointense lesions,
when compared with placebo and with the peginter-
feron beta-1a every 4 weeks treatment group at Week
24 and Week 48. In Year 2, there were further relative
reductions in the number of new or newly enlarging T2
hyperintense lesions in both continuous peginterferon
beta-1a groups compared with the delayed treatment
group (patients who received placebo in Year 1, and
were re-randomized to peginterferon beta-1a every 2 or
4 weeks in Year 2). The mean number of Gd + lesions
at 2 years was significantly lower in the peginterferon
beta-1a every 2 weeks group than in patients who
crossed over from placebo to peginterferon beta-1a
every 2 or 4 weeks at Week 48 (delayed treatment
group) [6]. Overall, patients receiving continuous
peginterferon beta-1a throughout the study displayed
better efficacy than the delayed treatment group, and
every 2 weeks dosing was more efficacious than every
4 weeks dosing. Peginterferon beta-1a was well toler-
ated across all treatment groups [6], and the safety pro-
file was maintained over the 2 years. In total there were
9 deaths (7 had received at least 1 dose of study drug),
which an independent data safety monitoring board
concluded were not likely related to study drug and did
not change the risk-benefit profile of peginterferon
beta-1a [6].
As treatments have improved, achievement of minimal
disease activity has become a realistic goal and ARR
endpoints have become a less sensitive measure with
which to evaluate new therapies in RRMS [7]. No evi-
dence of disease activity (NEDA; also known as free-
dom from measured disease activity [FMDA]) is a new,
more stringent clinical endpoint in MS incorporating
both clinical and MRI aspects of disease activity, [7, 8]
and has been evaluated in several clinical trials of
disease-modifying therapies (natalizumab, cladribine,
combiRx [interferon beta-1a and glatiramer acetate],
fingolimod, peginterferon beta-1a), although there has
been variation in the definition used [9–13]. Analysis
of NEDA in Year 1 of ADVANCE showed that signifi-
cantly more patients receiving peginterferon beta-1a
every 2 weeks achieved NEDA compared with the
peginterferon beta-1a every 4 weeks and placebo
groups [13]. The objectives of the present analyses
were to further explore MRI results, and determine the
proportion of patients who showed NEDA over the full
2 years of the Phase 3 ADVANCE study.
Methods
Study design and participants
The study design has been described previously [5, 6].
Briefly, ADVANCE was a randomized, multicenter, double-
blind, placebo-controlled Phase 3 cross-over study of
peginterferon beta-1a in patients with RRMS [5]. Pa-
tients who met the following key eligibility criteria were
recruited between June 2009 and November 2011: diag-
nosis of RRMS as defined by the McDonald criteria, [14]
age 18 − 65 years, Expanded Disability Status Scale [15]
(EDSS) score of 0 − 5, and at least two clinically docu-
mented relapses in the previous three years (at least one
within the 12 months prior to randomization). Patients
with progressive forms of MS, and those who had previ-
ously received interferon treatment for MS for longer
than four weeks’ duration, or less than six months prior
to baseline, were excluded. The protocol was approved
by each site’s institutional review board and was con-
ducted according to the International Conference on
Harmonization Guidelines for Good Clinical Practice
and the Declaration of Helsinki. Every patient provided
written informed consent prior to study entry.
Randomization and blinding
For the first year of the study, patients were randomly
assigned (1:1:1) to receive SC injections of placebo, or
peginterferon beta-1a 125 mcg every 2 weeks or every
4 weeks. To maintain dose blinding, all patients received
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an injection every 2 weeks; patients assigned to peginter-
feron beta-1a every 4 weeks received alternate injections
of placebo and peginterferon beta-1a. During Year 2, all
patients received dose-blinded peginterferon beta-1a,
with patients initially randomized to active treatment
continuing on the same dose regimen, and patients re-
ceiving placebo in Year 1 re-randomized to peginter-
feron beta-1a every 2 or 4 weeks at Week 48 [6].
All management, site personnel, investigators, and
patients were blinded to treatment assignment. Each
site used separate examining and treating neurologists,
thereby maintaining blinding for all treatment groups.
Study procedures, definitions and endpoints
Methods for the assessment of clinical and radiologic
endpoints in the ADVANCE study after 1 and 2 years
[5, 6] and details of additional Year 1 MRI analyses [13]
have been published in detail previously. Here we
describe methods relevant to the post-hoc analyses of
MRI data collected throughout the 2-year study, and
assessments of NEDA.
MRI scans obtained at screening and at Weeks 24, 48,
and 96 were evaluated centrally in a blinded manner at
NeuroRx Research, Montreal, Canada. MRI endpoints
derived from MRI scans included: number and volume
of T1-hypointense, T2-hyperintense and Gd + lesions;
number of new active lesions (sum of Gd+ plus non-
enhancing new or newly enlarging T2 hyperintense
lesions); whole brain volume; and magnetization
transfer ratio (MTR) in normal-appearing brain tissue
(NABT) and Gd + lesions. A summary of pulse se-
quences acquired and the analysis methods are provided
in Additional file 1 (Document S1: MRI acquisition
parameters and analysis).
Overall-NEDA, MRI-NEDA, and clinical-NEDA were
all evaluated for the periods 0–96 weeks and 48–96
weeks, and were defined as follows:
 Overall-NEDA: no evidence of clinical or MRI
disease activity over the stated time period. This
combines MRI-NEDA and Clinical-NEDA, both
defined below.
 MRI-NEDA: no Gd + lesions at any scan after the
beginning of the stated time period, and no new or
newly-enlarging T2 hyperintense lesions at the end
compared with the beginning of the period.
 Clinical-NEDA: no relapses1 and no onset of 12-
week confirmed disability progression2 over the
stated time period.
Statistical analysis
The MRI analysis population comprised patients in the
intent-to-treat (ITT) population who entered Year 2,
consented to participate in MRI analysis and had any
MRI data. Negative-binomial regression was used for
analysis of new or newly-enlarging hyperintense lesions
on T2-weighted images (adjusted for baseline number of
T2 hyperintense lesions); multiple logit regression was
used for the analysis of Gd + and new T1 hypointense
lesions (adjusted for baseline number of respective
lesions). The total number of new active lesions was de-
termined based on Gd + and T2 lesion numbers without
double counting. This was compared for each continuous
peginterferon beta-1a group versus the delayed treatment
group based on negative binomial regression, adjusted for
baseline number of Gd + lesions. Changes from baseline
in T2, T1 and Gd + lesion volumes, whole brain volume,
and MTR of NABT were compared using a Wilcoxon
rank-sum test. Post-hoc NEDA proportions were calcu-
lated directly, based on the definitions described above,
using data from all eligible patients.
The primary analysis used last observation carried for-
ward (LOCF) data (patients who did not have all measure-
ments, but had no evidence of disease activity on any of
the available measurements, were considered as NEDA).
In a sensitivity analysis, patients who did not have all MRI
measurements were excluded from the calculation of
NEDA, even if they had no evidence of disease activity on
available measurements. A logistic regression model was
used to calculate odds ratios (ORs) and corresponding
p-values for between-group comparisons. All data sets
are available upon request.
Results
Patient disposition and baseline characteristics
Patient demographics and baseline characteristics in the
overall study population were well balanced across the
treatment groups; mean age was 36–37 years, 70–72%
were women, and 81–82% were of white ethnic origin
[5]. Key baseline disease characteristics relevant to the
MRI and NEDA analyses are presented in Table 1. A
total of 1332 patients completed Year 1 of the study and
continued with active treatment in Year 2. The propor-
tion of patients who completed Year 2 was similar across
treatment groups: peginterferon beta-1a every 2 weeks,
391/438 (89%), peginterferon beta-1a every 4 weeks,
411/438 (94%), and delayed treatment 396/456 (87%) [6].
MRI Outcomes
The numbers of new/newly enlarging T2 lesions and Gd +
lesions during the 2 years of this study have been re-
ported previously and are summarized in Additional file 2:
Table S1 [6]. In brief, the mean number of new/newly en-
larging T2 lesions from baseline to Week 96, and mean
number of Gd + lesions at Week 96, were significantly
lower with peginterferon beta-1a every 2 weeks compared
with both delayed treatment and continuous peginterferon
beta-1a every 4 weeks [6].
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In the present analysis, we evaluated new T1-
hypointense lesions over 2 years, and found that, again,
significantly fewer T1 lesions formed during treatment
with peginterferon beta-1a every 2 weeks compared with
delayed treatment or peginterferon beta-1a every 4 weeks
(58% and 52% reduction, respectively; both p < 0.0001;
Fig. 1a). Patients in the peginterferon beta-1a every
2 weeks group also had, on average, significantly fewer
new active lesions from baseline to Week 96 (65% and
55% reduction vs delayed treatment and peginterferon
Table 1 Baseline disease characteristics (Calabresi et al. [5])
Characteristic Placebo Peginterferon beta-1a
Every 4 weeks Every 2 weeks
All patients, n 500 500 512
Relapses in the 12 months prior to enrolment, mean (SD) 1.6 (0.67) 1.5 (0.62) 1.6 (0.67)
Baseline EDSS score, mean (SD) 2.44 (1.18) 2.48 (1.24) 2.47 (1.26)
T2 lesions at baseline
Patients with available data, n 497 499 511
Mean number of lesions (SD) 50.6 (35.7) 51.4 (36.0) 48.7 (36.8)
Patients with no T2 lesions at baseline, n (%) 0 3 (<1) 4 (<1)
Gd + lesions at baseline
Patients with available data, n 497 498 510
Mean number of lesions (SD) 1.6 (3.8) 1.8 (5.4) 1.2 (3.4)
Patients with no Gd + lesions at baseline, n (%) 296 (59.6) 297 (59.6) 334 (65.5)
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Fig. 1 MRI lesions at Week 96: a new T1 hypointense lesions; b new-active lesions Gd+, gadolinium-enhancing lesions. MRI analysis population (ITT
population dosed in Year 2 with at least 1 MRI result). a P values based on multiple logit regression, adjusted for baseline number of T1 lesions. b
P values based on negative binomial regression, adjusted for baseline number of Gd + lesions
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beta-1a every 4 weeks, respectively; both p < 0.0001;
Fig. 1b). Additional file 3: Figure S1 shows two illustra-
tive examples of Gd + and T2 lesions that developed into
new T1-hypointense lesions over 2 years.
Total T2 hyperintense lesion volume decreased by a
mean of 0.23 cm3 from baseline to Week 96 in the
peginterferon beta-1a every 2 weeks group, while it in-
creased in the other groups (mean increases of 0.62 cm3
in the delayed treatment group and 0.36 cm3 in the
peginterferon beta-1a every 4 weeks; p < 0.0001 and p =
0.046, respectively, vs peginterferon beta-1a every
2 weeks; Table 2). A significantly smaller increase in T1
hypointense lesion volume was observed with continu-
ous peginterferon beta-1a every 2 weeks compared with
delayed treatment (0.48 cm3 and 0.87 cm3, respectively;
p < 0.0001; Table 2). Gd + lesion volume decreased slightly
in all groups, with no statistically significant difference
between groups (Table 2).
During the first year of the study, whole brain volume
decreased from baseline to a greater extent with pegin-
terferon beta-1a every 2 weeks than with delayed treat-
ment (p < 0.01 at Weeks 24 and 48); however, the
changes were small (<1%) and by Week 96, the reduc-
tion versus baseline was numerically smallest in the
peginterferon beta-1a every 2 weeks group (Fig. 2).
During the period from Week 24 to 96, reduction in
whole brain volume was significantly smaller with both
peginterferon beta-1a every 2 weeks and peginterferon
beta-1a every 4 weeks compared with delayed treat-
ment (Fig. 2 [inset]).
MTR of NABT was reduced in all groups. At each
time point, the reduction in NABT compared with base-
line was smallest in the peginterferon beta-1a every
2 weeks group. At Week 48 (the end of placebo treat-
ment for the delayed treatment group) MTR of NABT
had decreased by a mean of 0.12% in the peginterferon
beta-1a every 2 weeks group, compared with 0.39% in
the delayed treatment group (p = 0.05; Fig. 3).
Analyses of no evidence of disease activity (NEDA)
Over the two years of the study, a significantly higher
proportion of patients in the peginterferon beta-1a every
2 weeks group met overall-NEDA criteria compared
with the delayed treatment group (36.7% vs 15.8%; OR
3.09; p < 0.0001). This was also significantly higher than
the proportion in the peginterferon beta-1a every 4 weeks
group meeting overall-NEDA criteria (23.0%; OR 1.94; p
< 0.0001; Fig. 4a [LOCF analyses]). Both MRI and clin-
ical components of NEDA were achieved by signifi-
cantly higher proportions of patients in the
peginterferon beta-1a every 2 weeks group compared
with both delayed treatment and peginterferon beta-1a
every 4 weeks (ORs for MRI-NEDA 2.56 and 2.08,
respectively [both p < 0.0001]; ORs for clinical-NEDA
1.90 [p < 0.0001] and 1.39 [p = 0.016], respectively;
Fig. 4a). Sensitivity analyses to exclude patients who did
not have all MRI measurements for the calculation of
NEDA were consistent with the primary (LOCF) NEDA
analyses, with ORs the same or similar across all NEDA
assessments (Fig. 4b).
The proportions of patients meeting criteria for overall-,
MRI- and clinical-NEDA during Year 2 (Week 48 to
Week 96) were higher in all groups than proportions
achieving NEDA over the whole 2 years. Odds of achiev-
ing NEDA (overall and MRI and clinical components)
remained significantly higher with continuous peginter-
feron beta-1a every 2 weeks compared with both delayed
treatment (active treatment with peginterferon beta-1a
every 2 or 4 weeks in Year 2) and continuous peginter-
feron beta-1a every 4 weeks (Fig. 5).
Discussion
The outcomes from this analysis of MRI data and NEDA
status are consistent with those data previously reported
in the ADVANCE study, supporting the efficacy of
peginterferon beta-1a dosed every 2 weeks. Continuous
peginterferon beta-1a every 2 weeks consistently pro-
vided significant improvements in MRI lesion-based
endpoints (including reduced numbers and/or volumes
of new or newly-enlarging T2 lesions, new T1 lesions,
Gd + lesions, and new active lesions) versus delayed
treatment. Data from the first year of the ADVANCE
study showed that improvements observed in many of
these endpoints was statistically significant for peginter-
feron beta-1a every 2 weeks versus placebo at the first
brain MRI scheduled at Week 24, and sustained through
to Week 48 of the ADVANCE study [13]. Alongside re-
cently published 2-year data from the same study, [6]
Table 2 MRI lesion volumes at Week 96
Mean change from baseline (SD) Delayed
treatment
Peginterferon beta-1a
Every 4 weeks Every 2 weeks
Patients with available data, n 391 389 406
T2 hyperintense lesion volume, cm3 0.617 (2.2341) 0.362 (2.6841)† -0.231 (1.6103)a*
T1 hypointense lesion volume, cm3 0.869 (1.6907) 0.914 (2.4103) 0.478 (1.2417)*
Gd + lesion volume, cm3 -0.135 (0.5478) -0.164 (0.8676) -0.113 (0.4460)
Gd+ gadolinium-enhancing lesions; SD standard deviation *p < 0.0001, †p = 0.046 versus delayed treatment by Wilcoxon rank-sum test an = 407
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which shows significantly lower mean numbers of new
or newly-enlarging T2 and Gd + lesions when compared
to delayed treatment or peginterferon beta-1a every
4 weeks, the analyses of T1 lesions and new active le-
sions presented here suggest that the effect of peginter-
feron beta-1a every 2 weeks on reducing mean
numbers of lesions is further sustained throughout the
2-year study period.
We explored additional MRI measures besides lesions.
Analysis of whole brain volume at 96 weeks did not
reveal statistically significant treatment effects on
brain atrophy. However, this analysis could have been
confounded by the occurrence of pseudoatrophy, a
phenomenon whereby brain volume decreases signifi-
cantly during the first 6–12 months of anti-inflammatory
treatment, possibly reflecting resolution of edema and
inflammation present before treatment initiation [16].
Looking at change in brain volume from Week 24 to
Week 96, (to eliminate the first 6 months of treatment
in the continuous peginterferon beta-1a groups, when
the impact of pseudoatrophy was likely to be greatest)
the trend was reversed: there was a significantly smaller
Fig. 2 Percentage reduction in whole brain volume from baseline, and from Week 24 (inset). ITT population dosed in Year 2. *p < 0.05; †p < 0.01;
‡p < 0.001 vs delayed treatment (Wilcoxon rank-sum test)
Fig. 3 Percentage reduction in MTR of NABT. MTR, magnetization transfer ratio; NABT, normal appearing brain tissue. ITT population dosed in
Year 2. *p < 0.05 vs delayed treatment (Wilcoxon rank-sum test)
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reduction in whole brain volume with both peginterferon
beta-1a every 2 weeks and every 4 weeks, compared with
delayed treatment. This suggests that peginterferon beta-
1a could slow brain atrophy in the long term, although
the 2-year overall treatment duration in this study was not
sufficient to overcome the effects of pseudoatrophy in
the first few months, and comparisons may be further
confounded by onset of pseudoatrophy on initiation of
treatment in Year 2 in the delayed treatment group. Fur-
thermore, MTR measured in NABT over 96 weeks
showed a trend for improved outcomes with continuous
peginterferon every 2 weeks compared with delayed
treatment. If reductions in brain volume over time were
a result of true atrophy, it may be expected that this may
also coincide with myelin loss (reflected by a decrease in
MTR of NABT). Opposing trends for these measures
during the first year of treatment with peginterferon
beta-1a every 2 weeks (increased loss of brain volume
coinciding with decreased reduction in MTR of NABT)
support the suggestion that initial acceleration of loss of
brain volume resulted from pseudoatrophy. A significant
difference between peginterferon beta-1a every 2 weeks
Fig. 4 Proportions of patients with NEDA over 2 years (baseline to Week 96): a LOCF analysis; b observed dataa. MRI, magnetic resonance imaging;
NEDA, no evidence of disease activity; OR, odds ratio. aSensitivity analysis excluding patients with missing MRI data
Fig. 5 Proportions of patients with NEDA in Year 2 (Week 48–96). MRI, magnetic resonance imaging; NEDA, no evidence of disease activity; OR,
odds ratio. LOCF analysis (includes patients who did not have all measurements, but had no evidence of disease activity on any of the available
measurements). ITT population dosed in Year 2
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and delayed treatment in MTR of NABT change was
apparent at Week 48, but was not sustained to Week 96;
this may reflect a combination of attenuation of differ-
ences between the groups after peginterferon beta-1a
treatment was commenced in the delayed treatment
group and uncertainty in the point estimates given the
small changes and variability in this measurement.
In addition to the MRI data, the present NEDA ana-
lyses support the efficacy of peginterferon beta-1a treat-
ment every 2 weeks. Post-hoc analyses of efficacy data
from ADVANCE showed that proportions of patients
meeting criteria for overall-, MRI- and clinical-NEDA
from baseline to Week 96 were significantly higher with
peginterferon beta-1a every 2 weeks versus delayed
treatment. MRI components of the NEDA composite ap-
peared to be more sensitive to detecting treatment dif-
ferences than clinical components; a high proportion of
patients across all of the treatment groups met criteria
for clinical-NEDA, supporting the value of including
MRI components to support clinical-NEDA analyses.
Nonetheless, NEDA criteria appear to be sufficiently ro-
bust to withstand missing MRI data, since the sensitivity
analysis showed that inclusion of patients with missing
MRI data in the LOCF analysis did not notably affect
results. Currently, MRI-NEDA is defined as no Gd + le-
sions at Week 24, Week 48, or Week 96 and no new or
newly-enlarging T2 hyperintense lesions compared with
baseline over 96 weeks. Our analyses of MRI endpoints
alongside post-hoc NEDA analyses support the use of
this definition, since it reflects new active lesions
detected on MRI scans. T1 lesion formation was also
reduced during treatment with peginterferon beta-1a
every 2 weeks, but any added value of incorporating
this measure into the MRI-NEDA definition is not
clear. We found limitations to potential incorporation
of brain volume to the definition of NEDA: the small
changes observed over periods of clinical interest, such
as one or two years, and the noise in this measurement,
as well as the complication of pseudoatrophy, make it
unsuitable as a component of the MRI-NEDA and
overall-NEDA composite endpoints.
Our results are consistent with our previous analysis
of interim ADVANCE data, in which 39.8% of patients
in the peginterferon beta-1a every 2 weeks group, and
17.8% in the placebo group, achieved overall NEDA in
Year 1 (based on an LOCF analysis using the same NEDA
definition as the current analysis) [13]. In the current ana-
lysis, overall NEDA rates over 2 years (baseline to Week
96) were 36.7% in the continuous peginterferon beta-1a
group and 15.8% in the delayed treatment group. How-
ever, when we looked specifically at Year 2, these values
increased to 56.6% and 34.9%, respectively. This supports
the suggestion, based on our previous analysis, that it may
be preferable to begin to assess NEDA status after a
standard period of time (i.e., 6–12 months) following
initiation of treatment, since MRI components may be
affected by accrual of lesions early on before treatment
efficacy becomes apparent [13].
The finding that more than half of patients on pegin-
terferon beta-1a every 2 weeks achieved overall NEDA
in Year 2 is encouraging, as recent longitudinal study
in which NEDA status was monitored in a cohort of
patients with MS over 7 years suggested that NEDA
status at 2 years was a prognostic indicator for long
term outcomes [17]. Future analyses of data from the
ongoing ATTAIN study (an extension of ADVANCE)
will reveal whether NEDA status is maintained for a
high proportion of patients with longer-term peginter-
feron beta-1a treatment.
NEDA (sometimes referred to as FMDA or disease ac-
tivity free [DAF]) has been assessed for many of the
newer disease-modifying therapies becoming available
for the treatment of MS. Rates are quite variable, with
reported rates for overall-NEDA over 2 years ranging
from 18% to 46% in trials of teriflunomide, dimethyl
fumarate (DMF), fingolimod, natalizumab and cladribine
[9, 10, 12, 18–20]. Rates should be compared with cau-
tion, as differences in study design, patient populations
and MRI analysis techniques could contribute to vari-
ation, [8, 21, 22] although NEDA rates in placebo groups
in these trials did not vary as widely as those in active
treatment groups (7–16%). Considering differences in
terms of ORs helps to account for differences in the sen-
sitivity of the analyses, although ORs are not always pro-
vided in reporting of NEDA analyses. In a combined
post-hoc analysis of data from the DEFINE and CON-
FIRM studies, the OR for achieving overall NEDA with
DMF 240 mg twice daily versus placebo was 2.7 (23% vs
11%; p < 0.0001), [19] and in the CLARITY study ORs
for cladribine 3.5 mg/kg and 5.25 mg/kg versus placebo
were 4 · 28 and 4 · 62, respectively (44% and 46% vs 16%;
both p < 0.0001) [10]. Peginterferon beta-1a administered
continuously every 2 weeks for 2 years approximately
tripled the likelihood of achieving overall-NEDA (OR
3.09) compared with delayed treatment.
Determining the relevance of this data to real-world
experience will require further investigation, as patients
are rarely completely lesion-free and have varying
degrees of lesion activity. Interpretation is complicated
by “noise” in the measurement of new lesions related to
technical factors associated with the MRI acquisition
and rater variability [23]. In part for these reasons,
clinicians often look at a threshold for new lesions,
which may be different between physicians, hospitals,
and even different countries. A consensus on the use of
MRI techniques and analysis may prove to be very
beneficial to the study of MS, its pathophysiology, and
potential treatments.
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Conclusion
Analyses of MRI outcomes and NEDA outcomes, along
with efficacy for clinical endpoints previously reported,
[5, 6, 13] show that the efficacy of peginterferon beta-1a
is extended beyond the first year of the ADVANCE
study, illustrating the benefits of peginterferon beta-1a on
a number of different MRI outcomes as well as clinical-
NEDA status. SC peginterferon every 2 weeks is the least
frequently dosed interferon therapy for the treatment of
multiple sclerosis, and the present analysis further sup-
ports the use of this therapy in patients with RRMS.
Endnotes
1Relapses (confirmed by the independent neurologic
evaluation committee) were defined as new or recurrent
neurologic symptoms not associated with fever or infec-
tion, lasting for ≥24 h, and accompanied by new objective
neurologic findings, and separated from the onset of other
confirmed relapses by at least 30 days.
2Disability progression was defined as an increase in the
EDSS score of ≥1.0 point in patients with a baseline score
of ≥1.0, or an increase of ≥1.5 points in patients with a
baseline score of 0, confirmed after 12 or 24 weeks.
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